BCAX FY2025 EPS Estimate Increased by Cantor Fitzgerald

Bicara Therapeutics Inc. (NASDAQ:BCAX) – Stock analysts at Cantor Fitzgerald increased their FY2025 EPS estimates for Bicara Therapeutics in a research report issued to clients and investors on Monday, March 31st. Cantor Fitzgerald analyst E. Schmidt now expects that the company will earn ($1.81) per share for the year, up from their previous forecast of ($2.50). Cantor Fitzgerald currently has a “Overweight” rating and a $13.01 target price on the stock. The consensus estimate for Bicara Therapeutics’ current full-year earnings is ($2.59) per share.

Bicara Therapeutics (NASDAQ:BCAX) last released its earnings results on Thursday, March 27th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.08).

A number of other equities analysts also recently weighed in on the company. HC Wainwright upped their price target on Bicara Therapeutics from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, January 27th. Wedbush reissued an “outperform” rating and issued a $31.00 price objective on shares of Bicara Therapeutics in a research report on Thursday, March 27th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Bicara Therapeutics has an average rating of “Buy” and a consensus target price of $36.50.

Bicara Therapeutics Stock Down 2.8 %

BCAX stock opened at $12.66 on Wednesday. Bicara Therapeutics has a fifty-two week low of $11.10 and a fifty-two week high of $28.09. The business has a 50-day moving average of $13.07 and a 200-day moving average of $17.76.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. RA Capital Management L.P. bought a new position in shares of Bicara Therapeutics in the third quarter valued at $177,169,000. Red Tree Management LLC bought a new stake in Bicara Therapeutics during the fourth quarter worth $55,230,000. FMR LLC acquired a new stake in Bicara Therapeutics in the third quarter valued at $57,913,000. Adage Capital Partners GP L.L.C. grew its position in shares of Bicara Therapeutics by 171.9% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 2,175,265 shares of the company’s stock valued at $37,893,000 after acquiring an additional 1,375,265 shares during the period. Finally, Braidwell LP increased its stake in shares of Bicara Therapeutics by 20.7% during the 4th quarter. Braidwell LP now owns 2,000,659 shares of the company’s stock worth $34,851,000 after purchasing an additional 343,059 shares during the last quarter.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.